title: The involvement of bradykinin in adrenaline-induced pulmonary edema in rats.
abstract: We investigated the effect of endogenous bradykinin on adrenaline-induced pulmonary edema (PE) by blocking bradykinin receptors. In preliminary experiments, a bolus injection of adrenaline (ADR; 10 microg/kg) solution (10 microg/ml) was determined to be an edematogenic dose for inducing PE. The lung body weight index (LBI) and incidence of PE (IPE) were determined. The IPE and LBI of the group pretreated with Des-Arg9-[Leu8]-Bradykinin (DA-BK, 50 microg/kg, 50 microg/ml) increased significantly compared with those of the control group (p<0.05). On the other hand, there were no remarkable changes in IPE and LBI in the groups pretreated with Hoe140 (D-Arginyl-[Hyp3, Thi5, D-Tic7, Oic8]-Bradykinin (100 microg/kg, 100 microg/ml), captopril (20 mg/kg, 20 mg/ml) or L-NAME (1 mg/kg, 1 mg/ml). Moreover, the IPE and LBI of the group co-treated with L-NAME and DA-BK decreased compared with the DA-BK group (p<0.05). Thus, bradykinin aggravates adrenaline-induced PE through activation of the B2 receptor by the kallikreins as a result of the ADR administration, although the precise mechanism is not known.
authors.affiliation: Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hao
authors.forename: S
authors.initials: S
authors.lastname: Okamura
authors.forename: L M
authors.initials: LM
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Mineshita
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001835:Body Weight; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology*; D065168:Bradykinin Receptor Antagonists; D002216:Captopril / Q000494:pharmacology; D016009:Chi-Square Distribution; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004837:Epinephrine / Q000009:adverse effects*; D007610:Kallikreins / Q000502:physiology; D008168:Lung / Q000187:drug effects; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009929:Organ Size; D010646:Phentolamine / Q000494:pharmacology; D011654:Pulmonary Edema / Q000139:chemically induced*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000502:physiology; D013223:Statistics as Topic; D014662:Vasoconstrictor Agents / Q000009:adverse effects*
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065168:Bradykinin Receptor Antagonists; D004791:Enzyme Inhibitors; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin; D014662:Vasoconstrictor Agents; C024626:bradykinin, des-Arg(9)-; C065679:icatibant; D002216:Captopril; D007610:Kallikreins; D001920:Bradykinin; D019331:NG-Nitroarginine Methyl Ester; D004837:Epinephrine; D010646:Phentolamine